Ertugliflozin Production Cost Reports

The report provides a detailed analysis essential for establishing an Ertugliflozin production plant. It encompasses all critical aspects necessary for Ertugliflozin production, including the cost of Ertugliflozin production, Ertugliflozin plant cost, Ertugliflozin production costs, and the overall Ertugliflozin production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating an Ertugliflozin production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Ertugliflozin is a pharmaceutical drug primarily used to manage type 2 diabetes. It is primarily prescribed to help control blood sugar levels in adults by supporting the removal of excess glucose through urine. It works by blocking the sodium-glucose co-transporter 2 (SGLT2) in the kidneys, which helps lower blood sugar by increasing glucose excretion through urine. Its main application is as a part of antidiabetic therapy, either alone or in combination with other medications like metformin or sitagliptin. It helps improve insulin effectiveness and supports overall glucose balance in the body. It is also used to lower the risk of diabetes-related complications linked to high blood sugar levels. It is also being studied for its potential use in treating heart failure and chronic kidney disease.

The market for Ertugliflozin is driven by its application as a medication in long-term diabetes care and daily disease management, which significantly supports its demand in the medical and healthcare sectors. Its usage as an oral antidiabetic drug for the management of type 2 diabetes largely supports its demand in the pharmaceutical and healthcare sectors. Its usage as an oral drug in combination with other diabetes medicines for better sugar management also contributes to its demand in the medical and pharmaceutical industries.

The rising global prevalence of type 2 diabetes, along with increasing awareness of early disease management, also continues to boost its demand from hospitals, clinics, and drug manufacturers. In addition, industrial Ertugliflozin procurement is influenced by factors related to active ingredient availability, production costs, and strict regulatory requirements for diabetes medicines. Production efficiency, supplier reliability, compliance with quality standards, and well-managed distribution networks also affect its procurement decisions across the healthcare industry.

Raw Material for Ertugliflozin Production

According to the Ertugliflozin production plant project report, the major raw materials for Ertugliflozin production include Bromobenzene derivative ERTU-2, Pyrone ERTU-1, and Formaldehyde.

Production Process of Ertugliflozin

The extensive Ertugliflozin production cost report consists of the following industrial production process:

1. Production via Coupling Reaction: The production process of Ertugliflozin begins with the coupling of bromobenzene derivative ERTU-2 with pyrone ERTU-1 to form intermediate ERTU-3. This is followed by persilylation and selective monodesilylation to give ERTU-4. The resulting compound undergoes Parikh-Doering oxidation to give aldehyde ERTU-5. In the next step, ERTU-5 is treated with formaldehyde and base, triggering a series of transformations, including esterification, enolization, aldol reaction, and a crossed-Cannizzaro reduction to afford ERTU-6. Finally, bicyclic formation is carried out by reacting ERTU-6 with ERTU-7 in isopropanol, which produces the target compound, Ertugliflozin l-Pyroglutamic Acid.

Ertugliflozin is a sodium-glucose cotransporter 2 inhibitor used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It appears as a white to off-white solid powder. The molecular formula of the compound is C22H25ClO7, and its molecular weight is 436.89 g/mol. The compound has a density of 1.455 g/cm³ and a melting point of 65 to 66 degree Celsius. Additionally, it has a predicted boiling point of 630.5 degree Celsius. The compound is soluble in acetone, ethanol, and DMSO, slightly soluble in acetonitrile and ethyl acetate, and very slightly soluble in water. It is marketed under the brand name Steglatro. The compound may cause diabetic ketoacidosis, which is a serious, life-threatening condition that requires immediate medical attention. It is contraindicated in patients with severe renal impairment, end-stage renal disease, or those on dialysis. Extended exposure to this medication may cause serious health problems, including genital mycotic infections, urinary tract infections, acute kidney injury, hypotension, hypoglycemia, increased LDL cholesterol, ketoacidosis, and lower limb amputation. The medication should be stored at room temperature between 20 to 25 degree Celsius and protected from moisture.